Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study sets new gold standard for initial antiretroviral treatment of HIV infection

19.01.2006


Once-daily antiretroviral combination more effective and better tolerated than traditional drug ’cocktail’



An international team of AIDS researchers at Johns Hopkins and other institutions has found that a once-daily combination of three antiretroviral drugs works better as an initial treatment for HIV infection than another three-drug combination long considered the gold standard.

Reporting in the Jan. 19 issue of The New England Journal of Medicine, the researchers showed that after one year of treatment, a regimen of antiretroviral pills, called tenofovir DF (Viread) and emtricitabine (Emtriva), plus efavirenz (Sustiva), led to 14 percent more patients able to suppress levels of the virus, with fewer problems of anemia, fatigue and nausea than another widely used combination of antiretrovirals, zidovudine and lamivudine (AZT and 3TC, or Combivir), plus efavirenz.


"The implications are quite clear for patients with HIV who are about to start therapy: The simple combination of tenofovir and emtricitabine, plus efavirenz, is likely to be highly potent with minimal side effects or long-term toxicity," says the study’s lead author, Joel Gallant, M.D., M.P.H., associate professor and associate director of the AIDS Service at The Johns Hopkins University School of Medicine. Gallant notes that this regimen became even simpler in 2004, when tenofovir and emtricitabine were combined into a single pill, called Truvada.

The U.S. Centers for Disease Control and Prevention estimate that 40,000 Americans are newly infected each year with the virus that causes AIDS. Another quarter- million people already have HIV and are unaware of their infection and need for treatment.

Gallant cautions that the latest results may not apply to those patients already on zidovudine-lamivudine therapy and experiencing no problems. However, he points out that after the first year of the study, expected to continue for another two years, data already show early evidence of lipoatrophy (fat loss) in patients taking this regimen. Lipoatrophy is a known complication of some HIV medications that can lead to disfiguring changes in body shape. The researcher says that if fat loss gets worse during the remainder of the study in patients taking the zidovudine-lamivudine regimen, this would support switching to the tenofovir-emtricitabine regimen.

Tenofovir DF and emtricitabine are relatively new drugs, approved by the U.S. Food and Drug Administration (FDA) in 2001 and 2003 respectively. Zidovudine was the first antiretroviral drug, approved in 1987, and lamivudine became available in 1995. Since 1998, zidovudine and lamivudine have been available in a single-pill formulation called Combivir, which is prescribed as one pill taken twice daily.

In this study, both combinations included efavirenz, which, like the other drugs, prevents the genetic material, or RNA, in HIV from being turned into DNA. Efavirenz has been widely used for initial therapy since its approval in 1998.

Gallant’s study results are believed to be the first to demonstrate superiority of any regimen over the combination of zidovudine, lamivudine and efavirenz, which has been a popular and recommended combination for many years. The latest guidelines from the U.S. Department of Health and Human Services, released in 2005, recommend either combination as preferred initial treatments for HIV disease.

The study, known as Study 934, involved 517 patients from 67 sites across the United States, France, Germany, Italy, Spain and the United Kingdom. Participants included both men and women of all races, with an average age of 36, none of whom had been treated for their HIV infection. Half had viral loads in excess of 100,000 copies per milliliter of blood. Each participant was randomly assigned to start treatment with either the tenofovir-emtricitabine or zidovudine-lamivudine regimen, each in combination with efavirenz. Their progress was monitored through blood tests, pill counts and regular check-ups at their medical clinic.

Researchers found at the end of the first year of treatment that 80 percent of patients receiving the tenofovir-emtricitabine combination were able to suppress viral loads to undetectable levels (less than 50 copies per milliliter of blood), compared to 70 percent in the zidovudine-lamivudine group.

As viral levels dropped, the immune systems of patients who received the tenofovir-emtricitabine regimen also rebounded most, as measured by the increase in CD4 cells, which help fight infection. Their CD4 counts increased by an average of 190 cells per cubic millimeter of blood, while the average increase in the zidovudine-lamivudine group was 158 cells per cubic millimeter of blood.

"Both treatments are effective," adds Gallant. "But this study shows that we can do better, with fewer side effects and greater simplicity."

More side effects were reported in the zidovudine-lamivudine group, with 9 percent having to withdraw from the study, compared to just 4 percent in the tenofovir-emtricitabine group. The most common reason for stopping therapy in the zidovudine-lamivudine group was anemia, or loss of red blood cells. Discontinuation due to nausea, fatigue and dizziness, other side effects of zidovudine, was also more common with this regimen.

A subgroup of 100 patients had specialized tests to measure the amount of fat in the limbs at the end of the study. Patients in the zidovudine-lamivudine group had significantly less fat in their limbs by an average of more than 4 pounds, which may be a result of lipoatrophy, a recognized long-term side effect of zidovudine.

Study 934 quickly follows the results of previous research, Study 903, published by Gallant in July 2004 in The Journal of the American Medical Association, which showed that tenofovir DF was equally effective but had fewer side effects than another antiretroviral drug called stavudine (d4T, Zerit).

Adherence to taking pills as prescribed in Study 934 was also better in the tenofovir-emtricitabine group, at 90 percent, than for the zidovudine-lamivudine group, at 87 percent. Gallant attributes some of this difference to the fact that the former regimen could be taken once daily and was less likely to cause nausea than the latter combination, which had to be taken twice daily.

While Gallant notes that antiretroviral drug regimens have dramatically decreased in complexity in the last 10 years, he says that it would not have been unusual in 1996 for patients to have been taking combinations of up to 24 pills per day, in as many as five daily doses, and often with complicated food restrictions. However, the drug regimen in Study 934, he adds, required that patients take just two pills per day without any food restrictions. The three drugs should be available in a single-pill formulation within the year.

"The steady progress we have seen in simplifying antiretroviral therapy should make it a lot easier for patients to be adherent, which is critical to having a prolonged response and avoiding drug resistance," the researcher says.

Drug resistance was not a significant factor for either drug combination in the study. However, Gallant notes that 22 patients in the study were later found to have been resistant to efavirenz before starting medications, and these patients did not do as well on therapy as the overall group.

"This highlights the importance of testing for drug resistance before choosing a drug regimen, so the initial combination can be tailored based on the patient’s resistance results," he says.

Tenofovir is the only nucleotide reverse transcriptase inhibitor, but it is closely related to emtricitabine, zidovudine and lamivudine, which belong to a class of medications called nucleoside reverse transcriptase inhibitors. These drugs are combined with other AIDS drugs, either non-nucleoside reverse transcriptase inhibitors, such as efavirenz, or with protease inhibitors, which were not used in this study.

David March | EurekAlert!
Further information:
http://www.jhmi.edu

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>